OPKO Health (NASDAQ:OPK) Shares Up 3.1% – Here’s What Happened

OPKO Health, Inc. (NASDAQ:OPK) shares rose 3.1% on Tuesday . The company traded as high as $1.81 and last traded at $1.81. Approximately 1,335,916 shares were traded during trading, a decline of 71% from the average daily volume of 4,548,040 shares. The stock had previously closed at $1.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on OPK shares. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Monday. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a market cap of $1.31 billion, a PE ratio of -10.13 and a beta of 1.63. The company has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $1.55.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the purchase, the chief executive officer now directly owns 212,536,477 shares in the company, valued at $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders bought 1,389,971 shares of company stock valued at $2,124,442. Corporate insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently made changes to their positions in OPK. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in OPKO Health by 24.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock valued at $1,107,000 after acquiring an additional 148,322 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after purchasing an additional 949,671 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of OPKO Health by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 30,182 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in OPKO Health by 42.3% in the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after purchasing an additional 425,484 shares in the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.